Evidence map›Paper›PMID 37228092›Full record

ArticleThe journal of applied laboratory medicine2023

An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance?

Viviana Hernandez-Martinez, Jorge Duconge, Gualberto Ruaño

Abstract read
In one paragraph

Article in The journal of applied laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Viviana Hernandez-MartinezCollege of Pharmacy, Belmont University, Nashville, TN, United States.
Jorge DucongeSchool of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, United States.
Gualberto RuañoInstitute of Living at Hartford Hospital, Hartford, CT, United States.

Funding

Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Emma Fernandez-Repollet · 2017 to 2026
$35.8M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
NIMHD NIH HHS G12 MD007600NIMHD NIH HHS U54 MD007600
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PharmacogeneticsPharmacogenomic TestingHumans

Identifiers

PMID37228092
PMCPMC10585451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.